ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ocumension Therapeutics ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 2.66% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -303.35
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -18.96%, its profits have risen by 23.1%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -18.96% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ocumension Therapeutics for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ocumension Therapeutics
-18.96%
-0.13
58.62%
Hang Seng Hong Kong
8.76%
0.45
19.63%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
201.12%
EBIT Growth (5y)
2.66%
EBIT to Interest (avg)
-303.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.09
Tax Ratio
0.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.42
EV to EBIT
-16.90
EV to EBITDA
-30.23
EV to Capital Employed
1.49
EV to Sales
8.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.82%
ROE (Latest)
-6.77%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend22What is working for the Company
OPERATING CASH FLOW(Y)
Highest at HKD -275.73 MM
ROCE(HY)
Highest at -4.22%
NET SALES(Q)
Highest at HKD 558.68 MM
OPERATING PROFIT(Q)
Highest at HKD 52.25 MM
OPERATING PROFIT MARGIN(Q)
Highest at 9.35 %
INVENTORY TURNOVER RATIO(HY)
Highest at 8.21 times
PRE-TAX PROFIT(Q)
Highest at HKD -31.16 MM
NET PROFIT(Q)
Highest at HKD -31.23 MM
EPS(Q)
Highest at HKD -0.04
-8What is not working for the Company
INTEREST(HY)
At HKD 1.77 MM has Grown at 386.87%
RAW MATERIAL COST(Y)
Grown by 8.97% (YoY
CASH AND EQV(HY)
Lowest at HKD 609.82 MM
DEBT-EQUITY RATIO
(HY)
Highest at -9.78 %
Here's what is working for Ocumension Therapeutics
Net Sales
At HKD 558.68 MM has Grown at 106.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (HKD MM)
Operating Cash Flow
Highest at HKD -275.73 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (HKD MM)
Net Sales
Highest at HKD 558.68 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (HKD MM)
Operating Profit
Highest at HKD 52.25 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (HKD MM)
Operating Profit Margin
Highest at 9.35 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at HKD -31.16 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Pre-Tax Profit
At HKD -31.16 MM has Grown at 75.38%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Net Profit
Highest at HKD -31.23 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
Net Profit
At HKD -31.23 MM has Grown at 75.49%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD -0.04
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Inventory Turnover Ratio
Highest at 8.21 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Depreciation
Highest at HKD 80.04 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Here's what is not working for Ocumension Therapeutics
Interest
At HKD 1.77 MM has Grown at 386.87%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (HKD MM)
Cash and Eqv
Lowest at HKD 609.82 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -9.78 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 8.97% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
